Meta-analysis of studies using metformin as a reducer for liver cancer risk in diabetic patients
Open accessThe DOI matches its Crossref record; 58 of the 59 references it cites were found in a registry or an index.
Abstract
Metformin has garnered more interest as a chemo-preventive agent given the increased liver cancer risk in diabetic patients. This work was undertaken to better understand the effect of metformin use on liver cancer risk in diabetic patients.A comprehensive literature search was performed in PubMed, Embase, BIOSIS Previews, Web of Science, and Cochrane Library through July 30, 2016. Meta-analyses were performed using Stata version 12.0, with odds ratio (ORs) and 95% confidence intervals (CIs) as effect measures.Twenty-three studies were included. Meta-analysis of 19 studies involving 550,882 diabetic subjects suggested that metformin use reduced the ratio of liver cancer by 48% (OR = 0.52; 95% CI, 0.40-0.68) compared with nonusers. The protective effect was validated in all the exploratory subgroup analyses, except that pooled result of post hoc analyses of 2 randomized controlled trials found no significant difference between subjects with metformin and those without, with OR being 0.84 (95% CI, 0.10-6.83). After adjusting for hepatitis B/C virus infection, cirrhosis, obesity, behavioral factors, and time-related bias, the association was stable, pooled OR ranged from 0.42 to 0.75.A protective effect for liver cancer was found in diabetic metformin users. However, more randomized clinical evidence is still needed to verify the results.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures


Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“however, most of the available evidence was gathered from observational studies with varied designs and risk for bias.1781–1783”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [1781]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Metformin mayeither be neutral or modestly protective regarding cancer incidence and mortality;”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [1781]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“TZD therapy in general is not associated with other cancers and a modest reduction in overall cancer risk has been reported for pioglitazone.1781”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [1781]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Measuring inconsistency in meta-analyses
Higgins, J. P. T., Thompson, S. G., Deeks, J. J., & Altman, D. G. (2003) · BMJ · doi:10.1136/bmj.327.7414.557 · Cited by 63,139 · cited 1×
“1, and quantified by estimated I(2) (I(2)< 50% representing low heterogeneity, 50% I(2) 75% representing moderate heterogeneity, I(2) > 75% representing substantial heterogeneity).([16]) An inverse variance fixed-effects model was used to calculate when the test for heterogeneity was not statistically significant, oth…”
MethodBias in meta-analysis detected by a simple, graphical test
Egger, M., Smith, G. D., Schneider, M., & Minder, C. (1997) · BMJ · doi:10.1136/bmj.315.7109.629 · Cited by 56,722 · cited 1×
“1).([21,22]) All the statistical analyses were 2-sided and performed using Stata version 12.”
MethodStang, A. (2010) · European Journal of Epidemiology · doi:10.1007/s10654-010-9491-z · Cited by 17,396 · cited 2×
“Quality assessment Newcastle–Ottawa Scale [14] was used to assess the quality of observational studies and post hoc analyses of RCTs, which were treated as cohort studies to achieve quality assessment.”
MethodOperating characteristics of a rank correlation test for publication bias
Begg, C. B., & Mazumdar, M. (1994) · Biometrics · doi:10.2307/2533446 · Cited by 16,955
Statistical Aspects of the Analysis of Data From Retrospective Studies of Disease
(1959) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/22.4.719 · Cited by 14,689 · cited 1×
“An inverse variance fixed-effects model was used to calculate when the test for heterogeneity was not statistically significant, otherwise the DerSimonian–Laird random-effects model was employed.([17]) Sensitivity analyses were performed to assess the robustness of results.”
MethodGuyot, P., Ades, A., Ouwens, M. J., & Welton, N. J. (2012) · BMC Medical Research Methodology · doi:10.1186/1471-2288-12-9 · Cited by 2,526
Foretz, M., Hébrard, S., Leclerc, J., Zarrinpashneh, E., Soty, M., Mithieux, G., Sakamoto, K., Andreelli, F., & Viollet, B. (2010) · Journal of Clinical Investigation · doi:10.1172/jci40671 · Cited by 1,181
El–Serag, H. B., Hampel, H., & Javadi, F. (2006) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2005.12.007 · Cited by 826 · cited 2×
“Accumulating epidemiologic studies comparing the risk of liver cancer between those using metformin with those using other ADMs have shown somewhat variable results, and it was also endorsed that confounders were not well addressed in most studies.([2]) Several meta-analyses have been published to determine if a consi…”
BackgroundResultAdjusting for publication bias in the presence of heterogeneity
Terrin, N., Schmid, C. H., Lau, J., & Olkin, I. (2003) · Statistics in Medicine · doi:10.1002/sim.1461 · Cited by 809
Nathan, D. M., Buse, J. B., Davidson, M. B., Ferrannini, E., Holman, R. R., Sherwin, R., & Zinman, B. (2009) · Diabetologia · doi:10.1007/s00125-008-1157-y · Cited by 712
Research works printed but not linked: 2
- Aydin, 2013, Oral antidiabetics and insulins do not increase cancer risk, Acta Medica Mediterr, 29, 859
- Zheng, 2012, Metformin inhibits proliferation and colony formation ability through AMP-activated protein kinase in hepatocellular carcinoma cells, Diabetes, 61, A457
Cited by
Global epidemiology of NAFLD-related HCC: trends, predictions, risk factors and prevention
Huang, D. Q., El-Serag, H. B., & Loomba, R. (2021) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-020-00381-6 · Cited by 1,855
Risk factors and prevention of hepatocellular carcinoma in the era of precision medicine
Fujiwara, N., Friedman, S. L., Goossens, N., & Hoshida, Y. (2018) · Journal of Hepatology · doi:10.1016/j.jhep.2017.09.016 · Cited by 659
Blonde, L., Umpierrez, G. E., Reddy, S. S., McGill, J. B., Berga, S. L., Bush, M., Chandrasekaran, S., DeFronzo, R. A., Einhorn, D., Galindo, R. J., et al. (2022) · Endocrine Practice · doi:10.1016/j.eprac.2022.08.002 · Cited by 507
Campbell, J. M., Bellman, S. M., Stephenson, M. D., & Lisy., K. (2017) · Ageing Research Reviews · doi:10.1016/j.arr.2017.08.003 · Cited by 455
Loomba, R., Lim, J. K., Patton, H., & El-Serag, H. B. (2020) · Gastroenterology · doi:10.1053/j.gastro.2019.12.053 · Cited by 357
Metadata
- Authors
- Ma, S., Zheng, Y., Xiao, Y., Zhou, P., & Tan, H.
- Affiliations
- Central South University (CN)
- Corresponding author
- Tan, Hongzhuan
- Venue
- Medicine
- Published
- 2017-05
- Volume
- 96
- Issue
- 19
- Pages
- e6888
- ISSN
- 0025-7974 (ISSN-L)
- PMC
- PMC5428628
- OpenAlex
- W2613565875
- Cited by
- 89
- References
- 59
- Citations by year
- 2026: 2 · 2025: 5 · 2024: 8 · 2023: 10 · 2022: 16 · 2021: 15 · 2020: 9 · 2019: 11 · 2018: 10 · 2017: 3
- FWCI
- 0.84
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- Locations
- Medicine (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Metabolism, Diabetes, and Cancer
- Health Sciences › Medicine › Hepatology › Hepatocellular Carcinoma Treatment and Prognosis
- Health Sciences › Medicine › Oncology › Pancreatic and Hepatic Oncology Research
- Keywords
- metformin, liver cancer, hepatocellular carcinoma, diabetes mellitus, chemoprevention, cancer risk reduction, hepatocellular carcinoma incidence
- MeSH terms
- Animals, Diabetes Mellitus, Humans, Hypoglycemic Agents, Liver Neoplasms, Metformin, Risk, Diabetes Complications
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Meta-analysis of studies using metformin as a reducer for liver cancer risk in diabetic patients. https://app.cochat.ai/papers/10.1097/md.0000000000006888
- The paper
- Ma, S., Zheng, Y., Xiao, Y., Zhou, P., & Tan, H. (2017). Meta-analysis of studies using metformin as a reducer for liver cancer risk in diabetic patients. Medicine. https://doi.org/10.1097/md.0000000000006888
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.